Satellos Bioscience(MSLE)
$6.75-0.20 (-2.88%)
MSLE
Satellos Bioscience financials statements
$6.75
At close:-0.20 (-2.88%)
Satellos Bioscience (MSLE) Ratios
46 Followers
Satellos Bioscience Ratios
MSLE's free cash flow for Q2 2026 was C$-7.83M. For the 2026 fiscal year, MSLE's free cash flow was decreased by C$-20.00 and operating cash flow was C$-7.83M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.77 | 14.16 | 11.13 | 0.79 | 2.59 |
| Quick Ratio | 7.77 | 14.16 | 11.13 | 0.79 | 2.59 |
| Cash Ratio | 2.39 | 11.19 | 6.09 | 0.68 | 2.32 |
| Solvency Ratio | -6.18 | -5.45 | -4.38 | -3.88 | -7.29 |
| Operating Cash Flow Ratio | -5.86 | -4.84 | -4.00 | -2.04 | -2.39 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | C$ 27.73M | C$ 67.86M | C$ 36.70M | C$ -597.00K | C$ 3.34M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.15 | 1.08 | 1.09 | 1.84 | 1.20 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -88.73 | 0.00 | -5.63 |
| Interest Coverage Ratio | 0.00 | 0.00 | -87.36 | 0.00 | -4.81 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
| Net Debt to EBITDA | 0.36 | 2.05 | 1.41 | 0.24 | 1.06 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.70% | 100.00% | 100.00% | 100.04% | 100.00% |
| EBT Per EBIT | 93.36% | 101.05% | 102.75% | 134.28% | 327.32% |
| Return on Assets (ROA) | -79.51% | -38.48% | -35.87% | -182.64% | -123.20% |
| Return on Equity (ROE) | -91.26% | -41.41% | -39.06% | -336.06% | -147.92% |
| Return on Capital Employed (ROCE) | -97.07% | -40.98% | -38.02% | -250.16% | -45.19% |
| Return on Invested Capital (ROIC) | -97.07% | -40.98% | -38.02% | -250.09% | -45.19% |
| Return on Tangible Assets | -79.51% | -38.48% | -39.35% | -495.93% | -284.45% |
| Earnings Yield | -21.89% | -29.50% | -3.41% | -12.02% | -5.37% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.01 | 8.48 | 2.55 | 0.11 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -127143.70 | -54166.00 | -43.05 | -143.30 | -3435.82 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 127143.70 | 54166.00 | 43.05 | 143.30 | 3435.82 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.64 | -2.61 | -0.17 | -0.16 | -0.21 |
| Free Cash Flow Per Share | -1.65 | -2.61 | -0.17 | -0.16 | -0.21 |
| Dividend Paid and CapEx Coverage Ratio | -3935.27 | -4162.50 | -805.61 | -1927.67 | -694.69 |
| Capital Expenditure Coverage Ratio | -3935.27 | -4162.50 | -805.61 | -1927.67 | -694.69 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -20.77% | -26.22% | -3.11% | -6.14% | -1.74% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.58 | -3.39 | -29.37 | -8.32 | -18.63 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 4.17 | 1.40 | 11.47 | 27.96 | 27.56 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.81 | -3.81 | -32.14 | -16.28 | -57.31 |
| Price-to-Operating Cash Flow Ratio | -4.81 | -3.81 | -32.18 | -16.29 | -57.40 |
| Price-to-Earnings Growth (PEG) Ratio | 0.11 | -0.10 | 0.67 | 0.17 | -0.02 |
| Enterprise Value Multiple | -3.93 | -1.34 | -28.30 | -11.40 | -61.72 |
| Enterprise Value | 105.81M | 37.61M | 444.52M | 92.27M | 284.05M |
| EV to EBITDA | -3.93 | -1.34 | -28.30 | -11.40 | -61.72 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -4.41 | -1.51 | -30.62 | -15.95 | -56.35 |
| EV to Operating Cash Flow | -4.41 | -1.51 | -30.65 | -15.96 | -56.43 |
| Tangible Book Value Per Share | 1.90 | 7.09 | 0.43 | -0.02 | 0.14 |
| Shareholders’ Equity Per Share | 1.90 | 7.09 | 0.47 | 0.09 | 0.44 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | 0.00 | 0.00 | -0.00 | -0.06 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.73 | -2.94 | -0.18 | -0.32 | -0.64 |
| Tax Burden | 1.01 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.93 | 1.00 | 1.01 | 1.34 | 3.25 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.95 | 0.89 | 0.91 | 0.51 | 0.32 |
Currency in CAD
